Human-Derived Alternatives to Fetal Bovine Serum in Cell Culture

SummaryObjective: The need for an alternative to fetal bovine serum (FBS) is known to scientists and users involved in cell therapy or advanced therapy medicinal products. Human serum (huS) and platelet lysate (hPL) can be used as alternatives resulting in similar or even superior results concerning...

Full description

Saved in:
Bibliographic Details
Published in:Transfusion medicine and hemotherapy Vol. 40; no. 6; pp. 417 - 423
Main Authors: Witzeneder, Karin, Lindenmair, Andrea, Gabriel, Christian, Höller, Katharina, Theiß, Denise, Redl, Heinz, Hennerbichler, Simone
Format: Journal Article
Language:English
Published: Basel, Switzerland S. Karger GmbH 01-12-2013
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:SummaryObjective: The need for an alternative to fetal bovine serum (FBS) is known to scientists and users involved in cell therapy or advanced therapy medicinal products. Human serum (huS) and platelet lysate (hPL) can be used as alternatives resulting in similar or even superior results concerning cell expansion. Methods: We developed protocols for the production of huS and two types of hPL and tested them in the expansion of human fibroblasts and adipose tissue-derived stem cells (ASC). Quality control included cell counts (platelets, red and white blood cells), sterility testing, pH levels, total protein concentrations and growth factor levels. ASC and fibroblasts were expanded for three passages in media supplemented with FBS, huS or hPL and evaluated microscopically. Proliferation in terms of population doubling times (PDT) was determined. In case of ASC, differentiation was performed as well. Results: All three alternatives demonstrated shorter PDT for fibroblasts and ASC compared to FBS. Furthermore, ASC maintained their differentiation potential. Conclusion: We conclude that hPL and huS can be used as alternatives to FBS for the cultivation and expansion of cells intended for human use.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Karin Witzeneder and Andrea Lindenmair contributed equally to this publication
ISSN:1660-3796
1660-3818
DOI:10.1159/000356236